Drug Overview

Foslinanib (also known by its research code TT-00420) is a cutting-edge medication designed to treat advanced cancers that have stopped responding to standard treatments. It is classified as a Targeted Therapy and is often described as a “Smart Drug” because of its ability to strike multiple cancer-related targets at once.

Unlike traditional chemotherapy, which attacks all fast-growing cells, foslinanib is a “multikinase inhibitor.” It is engineered to find and block specific proteins that act as “on switches” for tumor growth and the development of new blood vessels that feed the tumor.

Generic name: Foslinanib
US Brand names: None (Currently an investigational drug)
Drug Class: Multikinase Inhibitor (Spectrum-selective Kinase Inhibitor)
Route of Administration: Oral (taken by mouth as a capsule or tablet)
FDA Approval Status: Investigational (Not yet approved for general use; has received “Fast Track” and “Orphan Drug” designations for specific rare cancers).

What Is It and How Does It Work? (Mechanism of Action)

To understand how foslinanib works, it helps to think of a cancer cell like a complicated machine with several power switches. If you only turn off one switch, the machine might find another way to keep running. Foslinanib is designed to turn off several of these switches at the same time.

At the molecular level, foslinanib targets several key signaling pathways:

FGFR (Fibroblast Growth Factor Receptor): Many tumors, especially in the bile duct, use this receptor to send growth signals. Foslinanib blocks this receptor to stop the “grow” command.
VEGFR (Vascular Endothelial Growth Factor Receptor): Tumors need their own blood supply to survive. By blocking VEGFR, foslinanib prevents the tumor from building new blood vessels, essentially starving it of nutrients.
Aurora Kinases: These are proteins that help cells divide. By inhibiting these, the drug makes it difficult for cancer cells to replicate their DNA and split into new cells.
JAK (Janus Kinase): This pathway is often involved in inflammation and helping cancer cells hide from the immune system.

By hitting all these targets simultaneously, foslinanib makes it much harder for the cancer to develop resistance.

FDA Approved Clinical Indications

As of early 2026, foslinanib is still in the clinical trial phase and does not have final FDA approval for commercial sale. However, it is being highly prioritized for the following conditions:

Oncological uses (Under Investigation):

Cholangiocarcinoma (Bile Duct Cancer): Specifically for patients with FGFR2 mutations who have already tried other therapies.
Triple-Negative Breast Cancer (TNBC): For advanced or metastatic cases where other treatments have failed.
Solid Tumors: General research is ongoing for various advanced tumors that show specific genetic mutations.

Non-oncological uses:

There are currently no non-oncological uses for this medication.

Dosage and Administration Protocols

Because foslinanib is an investigational drug, the dosage is strictly managed by doctors within clinical trials.

Protocol Detail	Standard Investigational Guidance
Standard Dose	Often studied at doses ranging from 10 mg to 20 mg.
Frequency	Taken once daily.
Administration	Oral; capsules should be swallowed whole with water.
Renal Insufficiency	Use with caution; specific dose-reduction data is still being gathered.
Hepatic Insufficiency	Since the liver processes this drug, patients with liver damage may require lower doses.

Clinical Efficacy and Research Results

Current clinical study data (2020–2025) has shown very encouraging results, particularly for patients with rare cancers.

Bile Duct Cancer (Cholangiocarcinoma): In Phase II trials, foslinanib has shown an Objective Response Rate (ORR) of approximately 25% to 35% in patients with specific FGFR2 changes. This means many patients saw significant tumor shrinkage.
Disease Control: In advanced solid tumor studies, the Disease Control Rate (DCR)—which includes patients whose tumors shrank or at least stopped growing—has been reported as high as 60% to 70% in specific study groups.
Survival Data: While long-term “Overall Survival” numbers are still being finalized, early data suggests that foslinanib can extend the time a patient lives without the disease getting worse (Progression-Free Survival) by several months compared to standard supportive care in late-stage patients.

Safety Profile and Side Effects

Foslinanib is generally better tolerated than intense chemotherapy, but because it blocks multiple pathways, it has a specific set of side effects.

Black Box Warning:

As an investigational drug, there is currently no official Black Box Warning. However, doctors monitor very closely for severe liver toxicity and high blood pressure.

Common side effects (>10%)

Hypertension (High Blood Pressure): Due to the blocking of blood vessel growth signals.
Palmar-Plantar Erythrodysesthesia: Also known as “Hand-Foot Syndrome,” causing redness, swelling, or pain on the palms and soles.
Fatigue: A general feeling of tiredness.
Diarrhea: Frequent or loose stools.

Serious adverse events

Liver Enzyme Elevation: Significant stress on the liver.
Proteinuria: Protein in the urine, which can indicate kidney stress.
Eye Problems: Specifically “serous retinal detachment,” which can cause blurry vision.

Management strategies

Hypertension: Most patients can continue treatment by taking standard blood pressure medications.
Hand-Foot Syndrome: Using thick, urea-based moisturizers and avoiding hot water can help protect the skin.

Research Areas

Foslinanib is a major focus in Combination Immunotherapy research. Scientists are currently testing if foslinanib can be used alongside “checkpoint inhibitors” (a type of immunotherapy). The theory is that foslinanib can “prime” the tumor by breaking down its defenses and blood vessels, making it much easier for the immune system to enter the tumor and destroy it.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed

Genetic Testing: To confirm if the tumor has the specific mutations (like FGFR2) that the drug targets.
Baseline Blood Pressure: To ensure it is under control before starting.
Eye Exam: To check the health of the retina.

Precautions during treatment

Regular Monitoring: Patients must have their blood pressure checked weekly during the first month.
Liver Health: Blood tests to check liver function (ALT/AST levels) are usually required every 2 weeks.

“Do’s and Don’ts” list

Do monitor your blood pressure at home and keep a log for your doctor.
Do report any sudden changes in your vision (blurriness or flashes) immediately.
Don’t take herbal supplements like St. John’s Wort, as they can interfere with the drug’s effectiveness.
Don’t ignore skin peeling or pain on your hands and feet; early treatment can prevent it from getting worse.

Legal Disclaimer

Standard Medical Disclaimer: This guide is for informational purposes only and does not constitute medical advice. Foslinanib is an investigational drug available only through clinical trials. Always consult with a licensed oncologist or healthcare professional to discuss treatment options, risks, and benefits specific to your medical history. Data provided is based on research available up to 2026 and is subject to change as more clinical information is released.